• Citer

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

par Perrot, Aurore;Lauwers-Cances, Valerie;Corre, Jill;Robillard, Nelly;Hulin, Cyrille;Chretien, Marie-Lorraine;Dejoie, Thomas;Maheo, Sabrina;Stoppa, Anne Marie;Pegourie, Brigitte;Karlin, Lionel;Garderet, Laurent;Arnulf, Bertrand;Doyen, Chantal;Meuleman, Nathalie ;Royer, Bruno;Eveillard, Jean-Richard;Benboubker, Lotfi;Dib, Mamoun;Decaux, Olivier;Jaccard, Arnaud;Belhadj, Karim;Brechignac, Sabine;Kolb, Brigitte;Fohrer, Cecile;Mohty, Mohamad;Macro, Margaret;Richardson, Paul G;Carlton, Victoria;Moorhead, Martin;Willis, Tom;Faham, Malek;Anderson, Kenneth Carl;Harousseau, Jean-Luc;Leleu, Xavier;Facon, Thierry;Moreau, Philippe;Attal, Michel;Avet-Loiseau, Herve;Munshi, Nikhil
Référence Blood, 132, 23, page (2456-2464)
Publication Publié, 2018-02-01

Article révisé par les pairs

• Détails
• Contenu

Titre:	Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
Auteur:	Perrot, Aurore; Lauwers-Cances, Valerie; Corre, Jill; Robillard, Nelly; Hulin, Cyrille; Chretien, Marie-Lorraine; Dejoie, Thomas; Maheo, Sabrina; Stoppa, Anne Marie; Pegourie, Brigitte; Karlin, Lionel; Garderet, Laurent; Arnulf, Bertrand; Doyen, Chantal; Meuleman, Nathalie; Royer, Bruno; Eveillard, Jean-Richard; Benboubker, Lotfi; Dib, Mamoun; Decaux, Olivier; Jaccard, Arnaud; Belhadj, Karim; Brechignac, Sabine; Kolb, Brigitte; Fohrer, Cecile; Mohty, Mohamad; Macro, Margaret; Richardson, Paul G; Carlton, Victoria; Moorhead, Martin; Willis, Tom; Faham, Malek; Anderson, Kenneth Carl; Harousseau, Jean-Luc; Leleu, Xavier; Facon, Thierry; Moreau, Philippe; Attal, Michel; Avet-Loiseau, Herve; Munshi, Nikhil
Informations sur la publication:	Blood, 132, 23, page (2456-2464)
Statut de publication:	Publié, 2018-02-01
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Aged
	Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
	Bone Marrow -- metabolism -- pathology
	Bortezomib -- administration & dosage
	Dexamethasone -- administration & dosage
	Disease-Free Survival
	Female
	Follow-Up Studies
	High-Throughput Nucleotide Sequencing
	Humans
	Lenalidomide -- administration & dosage
	Maintenance Chemotherapy
	Male
	Middle Aged
	Multiple Myeloma -- drug therapy -- genetics -- metabolism -- mortality
	Neoplasm, Residual
	Plasma Cells -- metabolism -- pathology
	Survival Rate
Langue:	Anglais
Identificateurs:	urn:issn:0006-4971
	info:doi/10.1182/blood-2018-06-858613
	info:pii/blood-2018-06-858613
	info:scp/85057753646
	info:pmid/30249784
	PMC6284215